Product Name: Bcr (588-594) pY591
Product Number: PE-04AEH99
| Size: | 200 µg | Price: | 47.00 | |
| 1 mg | $US | 94.00 | ||
| 5 mg | 206.00 |
Peptide Name: Bcr (588-594) pY591
Product Use: Services as a blocking peptide for use with the Bcr-pY591 rabbit polyclonal antibody (Cat. No.: AB-PK539) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the Rho-GEF domain. One of the main in vivo phosphorylation sites in Bcr. The effect of its phosphorylation is unclear.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: LGV-pY-RAF
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Product Use: Services as a blocking peptide for use with the Bcr-pY591 rabbit polyclonal antibody (Cat. No.: AB-PK539) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the Rho-GEF domain. One of the main in vivo phosphorylation sites in Bcr. The effect of its phosphorylation is unclear.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: LGV-pY-RAF
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1078.18 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Bcr - pY591 phosphosite-specific antibody (Cat. No.: AB-PK539)
Peptide Molecular Mass Calculated: 1078.18 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Bcr - pY591 phosphosite-specific antibody (Cat. No.: AB-PK539)
Scientific Background: Bcr (Bcr1, breakpoint cluster region) is a protein-serine/threonine kinase of the Atypical group and Bcr family. It features a protein-serine/threonine kinase domain at its N-terminus and also acts as a GTPase-activating protein for Rac1 and Cdc42 by virtue of a C-terminal domain. Bcr promotes the exchange of Rac1 or Cdc42-bound GDP by GTP, thereby activating them. It is ubiquitously expressed, with highest expression in brain and hematopoietic tissue. The function of physiological Bcr is unclear. Bcr appears to be an oncoprotein (OP). The Bcr gene is located on chromosome 22q11. 2, which is the site of a common breakpoint for chromosomal translocations commonly found in specific human cancers. These chromosomal translocations are observed in chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL) and produce two alternative forms of the Philadelphia chromosome, in which different sets of exons from the Bcr gene are joined to a common group of exons from the Abl1 gene. This creates two chimeric oncogene products referred to as p210(Bcr-Abl) and p185(Bcr-Abl), which both display oncogenic tyrosine kinase activity. The inhibtion of myeloid precursor cell differentiation is a key feature of the cancer progression in patients with CML that express the p210(Bcr-Abl) oncoprotein. This differentiation arrest is mediated through the transcriptional suppression of the granulocyte-stimulating factor receptor (CSF3R) gene through phosphorylation by the Abl kinase domain of the fusion protein. In animal studies, transplantation of a retrovirus encoding the p210(Bcr-Abl) oncoprotein into irradiated immuno-deficient mice induced hematologic malignancies with similar features as human leukemia, specifically CML. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis.
© Kinexus Bioinformatics Corporation 2017